47 results about "TWEAK RECEPTOR" patented technology

The present application relates to a GLP-1 receptor agonist, which is a compound of formula (II) or a pharmaceutically acceptable salt thereof, and a method for treating or preventing a GLP-1 receptor-mediated disease or disorder or regulating a GLP-1 receptor.

The present invention relates to compounds that inhibit the toxic activity of the extrasynaptic NMDA receptor, in particular by inhibiting the formation of the NMDA receptor / TRPM4 complex. In particular, the present invention relates to diamino compounds according to general formula I and their use in medicine, in particular for the treatment of nervous system diseases, such as neurodegenerative diseases.

The invention relates to the field of cosmetics, in particular to a sialic acid composition with an acne removing effect, a preparation method of the sialic acid composition and cosmetics. The composition is prepared from 8%-20% of sialic acid, 10%-25% of ectoine, 5%-15% of a humectant, 0.1%-1% of a thickening agent, 0.05%-0.5% of a pH regulator and the balance of water. Cubilose acid can promote collagen synthesis, repair damaged skin barrier and reduce inflammatory response caused by external stimulation, and acne generation is inhibited from acne inducement; meanwhile, the sialic acid can inhibit release of proinflammatory factors such as TNF-alpha and IL-6 by adjusting a TLR receptor signal channel, red and swollen pox is relieved, and the generated pox is inhibited from the aspect of inhibiting inflammation; the sialic acid is non-irritant, and can slightly promote cutin renewal under high concentration, so that the problems of skin desquamation, sensitivity and the like caused by barrier injury can be effectively avoided. Ectoin is compounded, so that the Ectoin and sialic acid can generate a synergistic interaction effect.

The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and / or dissemination. The compounds contemplated in the disclosure are useful in the prevention, treatment, and / or amelioration of virus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and / or an agent that treats, ameliorates, and / or prevents one or more virus infection symptoms and / or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma1) or Sigma-2 receptor (also known as Sigma2 or TMEM97). In certain embodiments, Sigma1 inhibitors / antagonists that cause and / or trigger ER stress and / or autophagy are useful within the methods of the disclosure.

The invention discloses an engineered exosome containing gp96 antigen information as well as a preparation method and application of the engineered exosome, and belongs to the technical field of exosomes. The invention solves the problem of how to further improve the effect of the exosome in the aspect of treating diseases. The exosome disclosed by the invention is derived from stem cells which are subjected to gp96 pretreatment and over-express gp96 antigen information. When the gp96 is combined with the exosome, the function of the exosome can be enhanced, so that the antigen information molecules carried by the gp96 can be more effectively transmitted into specific cells, and the physiological function of recipient cells is adjusted. The combination has potential application value in treatment of inflammation-related diseases such as osteoarthritis and the like.

The present disclosure provides antibodies and antibody fragments thereof that bind to IL-25. The antibodies and antibody fragments thereof of the present disclosure can modulate the biological activity of the IL-25 / IL-25 receptor signaling axis, and thus are useful in the treatment of type 2 inflammatory diseases, autoimmune diseases, allergic diseases, or cancers.

The application relates to a compound of Formula (I):or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.

Peptide conjugates comprising a peptide selected from a peptide that modulates the PYY receptor, a peptide that modulates both the GLP-1 receptor and the GCG receptor, a peptide that modulates both the GLP-1 receptor and the GIP receptor, and a peptide that modulates the GLP-1 receptor; and a staple attached to the peptide at a first amino acid and a second amino acid are disclosed herein. Also provided are peptide conjugates comprising prolactin-releasing peptide. The peptide conjugates may be used for treating conditions such as obesity. Further provided are stapled prolactin-releasing peptide.

The present disclosure relates generally to adenosine receptor modulator compounds of formula (I), and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of A2B adenosine receptor activity.

Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a mutant Notch NRR (Negative Regulatory Region). Another aspect of the invention relates to a protease-dependent synthetic protein. Engineered cells comprising the synthetic protein are additionally described herein.

The present invention discloses an aryl group-containing amine compound, its preparation method, and use. The aryl group-containing amine compound is represented by formula (I), and has the function of regulating NMDA receptor and / or monoamine transporter and / or sigma receptor activity, and can be used to prepare a medicament for treating and / or preventing diseases associated with NMDA receptors and / or monoamine transporters and / or sigma receptors, particularly central nervous system diseases. JPEG2025538201000350.jpg4951

The invention provides preparation of a low-background nanoprobe for detecting ONOO <-> / ClO <-> and whole blood detection, a multifunctional fluorescent nanoprobe is designed based on a donor-receptor one-to-many integrated sensing strategy based on FRET and blood self-fluorescence inhibition, a donor effectively inhibits blood self-fluorescence through an inner filter effect, and by adjusting the proportion of the receptor to the donor, the self-fluorescence of the blood can be effectively inhibited, so that the ONOO <-> / ClO <-> can be detected, and the ONOO <-> / ClO <-> can be detected. FRET effect is utilized to effectively quench donor fluorescence, so that zero background of a whole blood detection system is realized. Benefited from extremely low background fluorescence, the invention successfully detects the level of endogenous ONOO- / ClO-in the whole blood of mice with sepsis and hemolytic diseases, monitors the change of the level of ONOO- / ClO-in the process of sepsis and hemolytic diseases, and proves that the concentration of ONOO- / ClO-is positively correlated with the severity of diseases. The strategy is simple to operate and does not need complex synthesis and other operations. The zero-background generalized sensing strategy in whole blood detection provides a valuable insight for designing a fluorescent probe for detecting endogenous substances in blood.

The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament.The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

The present disclosure provides antibodies and antibody fragments thereof that bind to IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-23 receptor signaling axis and are therefore useful for the treatment of immune-mediated inflammatory disorders.

The present invention relates to compounds that inhibit the toxic activity of extrasynaptic NMDA receptors, particularly by inhibiting the formation of the NMDA receptor / TRPM4 complex. In particular, the present invention relates to diamine compounds according to general formula I and their use in medicine, especially in the treatment of neurological disorders such as neurodegenerative disorders.

This document provides compounds and their compositions for modulating the S1P5 receptor. In some cases, the compounds and compositions are provided for the treatment of neurological diseases.

The present application relates to a novel GLP-1 receptor agonist, which is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing GLP-1 receptor mediated diseases or disorders or modulating GLP-1 receptor. Formula (I).

The present application relates to a GLP-1 receptor agonist, which is a compound of formula (II) or a pharmaceutically acceptable salt thereof, and a method for treating or preventing a GLP-1 receptor-mediated disease or disorder or regulating a GLP-1 receptor.

The present invention relates to compounds inhibiting the toxic activity of extrasynaptic NMDA receptors, in particular by inhibiting the formation of NMDA receptor / TRPM4 complexes. In particular, the present invention relates to diamine-based compounds according to general formula I and their use in medicine, in particular for treating neurological diseases such as neurodegenerative diseases.

The invention relates to the technical field of microorganisms, in particular to lactobacillus kefir and application thereof in the aspect of regulating animal immune functions. The invention provides Kefir lactobacillus brachyphyllum Fanghua, and the preservation number of the Kefir lactobacillus brachyphyllum Fanghua is CGMCC (China General Microbiological Culture Collection Center) NO.27733 Research finds that compared with an immunosuppression model mouse constructed by using hydrocortisone, the weight of immune organs thymus and spleen can be increased, the number of peripheral blood leucocytes can be increased, and immune cell composition and expression of inflammation-related genes can be changed when the mouse is fed with the Lactobacillus kefir Fanghua. Besides, after the excrement of the aged mice fed with the lactobacillus kefir Fanghua is transplanted to the sterile mice, compared with excrement only transplanted to the aged mice, the content of dendritic cells in the spleen of the receptor mice can be reduced, differentiation of helper T cells can be inhibited, expression of inflammation-related genes can be remarkably reduced, and the inflammation-related effects can be improved. Further, the immune inflammatory response of the receptor mouse is regulated.

The present application relates to a GLP-1 receptor agonist, a pharmaceutically acceptable salt thereof, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a method thereof for treating or preventing a GLP-1 receptor mediated disease or disorder or modulating a GLP-1 receptor. # imgabs0 #

The present invention relates to compounds useful in the modulation of the sigma-1 receptor (S1R). The present invention also relates to the use of these compounds in the treatment of sigma-1 receptor (S1R) associated diseases and disorders, for instance, diseases and disorders associated with ER stress, and diseases and disorders which would benefit from sigma-1 receptor (S1R) activation.

The disclosures herein relate to novel compounds of formulawherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

The present application relates to a heterocyclic GLP-1 derivative, a pharmaceutically acceptable salt thereof, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a method of treating or preventing a GLP-1 receptor mediated disease or disorder or modulating a GLP-1 receptor thereof. # imgabs0 #

To provide modulation of antibody effector functions.SOLUTION: There are provided methods of modulating Fc gamma Receptor (FcγR)-mediated cytotoxicity of an antibody composition. In exemplary embodiments, the method comprises (1) increasing or decreasing an amount of terminal β-galactose at an N-297 glycosylation site of panitumumab, or increasing or decreasing an amount of panitumumab molecules that comprise G1, G1a, G1b and / or G2 galactosylated glycan at the N-297 site, (2) increasing or decreasing the amount of panitumumab molecules that comprise fucosylated glycan at the N-297 site, or increasing or decreasing the amount of panitumumab molecules that comprise afucosylated glycan at the N-297 site, and (3) increasing or decreasing the amount of panitumumab molecules that comprise high-mannose glycan at the N-297 site.SELECTED DRAWING: None

Provided are methods of modifying the solubility properties of individual peptides and sets of peptides of which an example embodiment includes sets of overlapping peptides prepared to be suitable for use as vaccines to modulate the immune responses of recipients. The peptides are modified to have the requisite solubility properties for tissue delivery by precipitation without extraneous binding and modification of antigenicity. According to example embodiments. the modified peptides are suitable to be used in TDBP / VDBP methods. Also provided herein are the solubility-modified peptides themselves and kits that include them. Further provided are methods of administering solubility-modified peptides with the requisite solubility properties for tissue delivery by precipitation.